

**Breakthrough innovation in fast and certain HER-2 Positive Breast Cancer diagnosis.
Our vision to revolutionize biopsies and histopathology diagnosing
SDS Optic - Lifesaving Innovations**



Co-funded by the Horizon 2020 programme
of the European Union

June 2018






8.2 milion people die each year from cancer, an estimated 13% of all deaths worldwide (*522.000 women die of breast cancer every single year*)

70% the increase in new cases of cancer expected over the next 2 decades (from 14 milion in 2012)

>100 cancer types exist, each requiring unique diagnosis and treatment.

There are about 1.7 million new cases and 522 000 deaths from breast cancer each year.

Source: World Health Organization
<http://www.who.int/mediacentre/factsheets/fs297/en/>



Major FACTS on Cancer

Fact

There are more than 100 types of cancers; any part of the body can be affected.

Fact

Worldwide, the 5 most common types of cancer that kill men are (in order of frequency): lung, stomach, liver, colorectal and oesophagus.

Fact

Worldwide, the 5 most common types of cancer that kill women are (in the order of frequency): breast, lung, stomach, colorectal and cervical. In many developing countries, cervical cancer is the most common cancer.


Fact

Tobacco use is the single largest preventable cause of cancer in the world causing 22% of cancer deaths

Fact

Cancers of major public health relevance such as breast, cervical and colorectal cancer can be cured if detected early and treated adequately.





Worldwide Medical Device Innovation Fiber Optic Microprobe for HER-2 Breast Cancer Diagnostics



Key Benefits of our innovative technology

As stated by world-renowned oncologist (board member of ESSO)

- Real-Time biopsy & histopathology result
- Objectivity of the diagnostic results – numerical result
- No need for the tissue acquisition from the patient's body
- In Vivo examination possibility
- Potentially wide range of tumor markers, HER2 first in place
- Possibility to document and archive results



SDS Optic diagnostic microprobe has a clear advantages in HER2 breast cancer testing



- The SDS MicroProbe is a **minimally invasive** medical device capable of **real-time diagnostics of selected tumor biomarker types** in a patient – currently HER2 breast cancer and HER2 stomach cancer
- It identifies cancer cells with laser fiber optics of specific frequency and by using innovative components at the tip of the microprobe (PCT PETENT PENDING)
- The SDS MicroProbe **will shorten the HER2 tumor marker level testing from several days or weeks to several minutes**, without painful tissue biopsy and laboratory involvement
- **SDS Optic Microprobe combines traditional biopsy and histopathology** (f.e. FISH or IHC as current gold standards)
- **Real-Time HER2 diagnostics is a complete groundbreaking milestone in fighting cancer** as it can allow immediate launch of anti-HER2 targeted treatment (f.e. Herceptin). **This can lead to saving 30% women diagnosed with HER2+ breast cancer**
- **SDS Optic has been awarded largest ever SME Instrument Horizon2020 grant from EU Commission (€4M)** which covers clinical trials, technology scale-up and commercialization



The National Centre
for Research and Development



Co-funded by the Horizon 2020 programme
of the European Union



lublin
medicine



Thank you

SDS OPTIC LLC

Konstantynow 1F, 20-708 Lublin , POLAND

office (+48) 81 501 94 63

www.sdsoptic.pl

office@sdsoptic.pl